Product Description
Epoprostenol is a synthetic analogue of the naturally occurring eicosanoid prostacyclin (prostaglandin I2 or PGI2), which is the main metabolite of arachidonic acid (Sourced from: https://err.ersjournals.com/content/26/143/160055)
Mechanisms of Action: PGI2 Agonist, PA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Inhalant
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Chile | Colombia | Czech | Denmark | Estonia | France | Germany | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Japan | Luxembourg | Malta | Netherlands | New Zealand | Norway | Poland | Portugal | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: Eastern America
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hypertension, Pulmonary
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05427162 |
CR109201 | P1 |
Completed |
Hypertension, Pulmonary |
2023-12-05 |
12% |
2024-03-01 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |